Li K, Zhang Y, Liu X, Liu Y, Gu Z, Cao H, et al. Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies. Cancer Discov. 2020;10:724-745 pubmed publisher

Piao L, Dorotea D, Jiang S, Koh E, Oh G, Ha H. Impaired Peroxisomal Fitness in Obese Mice, a Vicious Cycle Exacerbating Adipocyte Dysfunction via Oxidative Stress. Antioxid Redox Signal. 2019;31:1339-1351 pubmed publisher

Nogueira Recalde U, Lorenzo Gómez I, Blanco F, Loza M, Grassi D, Shirinsky V, et al. Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine. 2019;45:588-605 pubmed publisher

Majeed Y, Upadhyay R, Alhousseiny S, Taha T, Musthak A, Shaheen Y, et al. Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. Sci Rep. 2019;9:6316 pubmed publisher

D Aniello E, Iannotti F, Falkenberg L, Martella A, Gentile A, De Maio F, et al. In Silico Identification and Experimental Validation of (-)-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator. Mar Drugs. 2019;17: pubmed publisher

Luty M, Piwowarczyk K, Łabędź Masłowska A, Wrobel T, Szczygieł M, Catapano J, et al. Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel. Cancers (Basel). 2019;11: pubmed publisher

Ham Y, Song H, Kwon J, Jeon H, Baek H, Kim C, et al. Effects of fermented Sorghum bicolor L. Moench extract on inflammation and thickness in a vascular cell and atherosclerotic mice model. J Nat Med. 2019;73:34-46 pubmed publisher

Vitale R, D Aniello E, Gorbi S, Martella A, Silvestri C, Giuliani M, et al. Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. Mar Drugs. 2018;16: pubmed publisher

Theil F, Milsmann J, Kyeremateng S, Anantharaman S, Rosenberg J, van Lishaut H. Extraordinary Long-Term-Stability in Kinetically Stabilized Amorphous Solid Dispersions of Fenofibrate. Mol Pharm. 2017;14:4636-4647 pubmed publisher

Wei W, Lu X, Wang Z, Perez B, Liu J, Wu C, et al. Single-component solid lipid nanocarriers prepared with ultra-long chain amphiphilic lipids. J Colloid Interface Sci. 2017;505:392-401 pubmed publisher

Reza M, Hossain M, Damte D, Jo W, Hsu W, Park S. Hypolipidemic and Hepatic Steatosis Preventing Activities of the Wood Ear Medicinal Mushroom Auricularia auricula-judae (Higher Basidiomycetes) Ethanol Extract In Vivo and In Vitro. Int J Med Mushrooms. 2015;17:723-34 pubmed

Helmy M, Helmy M, El Mas M. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. PLoS ONE. 2015;10:e0142303 pubmed publisher

Kumar V, Cabana H. Towards high potential magnetic biocatalysts for on-demand elimination of pharmaceuticals. Bioresour Technol. 2016;200:81-9 pubmed publisher

Rein Fischboeck L, Krautbauer S, Eisinger K, Pohl R, Meier E, Weiss T, et al. Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease. Biochem Biophys Res Commun. 2015;467:377-82 pubmed publisher

Kim Y, Lee K, Hwang S, Chang H, Kim K, Harris R, et al. Inhibition of cereblon by fenofibrate ameliorates alcoholic liver disease by enhancing AMPK. Biochim Biophys Acta. 2015;1852:2662-70 pubmed publisher

Jafri K, Taylor L, Nezamzadeh M, Baker J, Mehta N, Bartels C, et al. Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. BMC Musculoskelet Disord. 2015;16:237 pubmed publisher

O Shea J, Faisal W, Ruane O Hora T, Devine K, Kostewicz E, O Driscoll C, et al. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments. Eur J Pharm Biopharm. 2015;96:207-16 pubmed publisher

Quesada L, Gomila I, Fe A, Servera M, Yates C, Morell Garcia D, et al. Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results. J Anal Toxicol. 2015;39:734-40 pubmed publisher

He Y, Ho C. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development. J Pharm Sci. 2015;104:3237-58 pubmed publisher

Yang L, Shao Y, Han H. Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability. Eur J Pharm Sci. 2015;78:103-10 pubmed publisher

Fukami T, Kariya M, Kurokawa T, Iida A, Nakajima M. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. Eur J Pharm Sci. 2015;78:47-53 pubmed publisher

Filippatos T, Elisaf M. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481-93 pubmed publisher

Tatachar A, Pio M, Yeung D, Moss E, Chow D, Boatright S, et al. Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis. J Clin Lipidol. 2015;9:326-33 pubmed publisher

Nishida H, Hirota M, Seto Y, Suzuki G, Kato M, Kitagaki M, et al. Non-animal photosafety screening for complex cosmetic ingredients with photochemical and photobiochemical assessment tools. Regul Toxicol Pharmacol. 2015;72:578-85 pubmed publisher

Althurwi H, Maayah Z, Elshenawy O, El Kadi A. Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol. Drug Metab Dispos. 2015;43:1254-66 pubmed publisher

Hens B, Brouwers J, Corsetti M, Augustijns P. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. Eur J Pharm Sci. 2015;77:40-7 pubmed publisher

El Haggar S, Mostafa T. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. Hepatol Int. 2015;9:471-9 pubmed publisher

Chan S, Zeng X, Sun R, Jo E, Zhou X, Wang H, et al. Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice. Biochim Biophys Acta. 2015;1852:1511-9 pubmed publisher

Grabacka M, Waligórski P, Zapata A, Blake D, Wyczechowska D, Wilk A, et al. Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier. J Physiol Pharmacol. 2015;66:233-47 pubmed

Zhang N, Lu Y, Shen X, Bao Y, Cheng J, Chen L, et al. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice. Pharmacology. 2015;95:173-80 pubmed publisher

Verbeeck R, De Niet S, Lebrun S, Tremege M, Rennie T, Coffiner M, et al. The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions. J Pharm Pharm Sci. 2015;18:61-7 pubmed

Bahloul B, Lassoued M, Seguin J, Lai Kuen R, Dhotel H, Sfar S, et al. Self-emulsifying drug delivery system developed by the HLB-RSM approach: Characterization by transmission electron microscopy and pharmacokinetic study. Int J Pharm. 2015;487:56-63 pubmed publisher

César F, Rudnicki M, de las Heras B, Boscá L, Lima M, Pitta I, et al. New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice. Vascul Pharmacol. 2015;71:174-80 pubmed publisher

Su C, Shi A, Cao G, Tao T, Chen R, Hu Z, et al. Fenofibrate suppressed proliferation and migration of human neuroblastoma cells via oxidative stress dependent of TXNIP upregulation. Biochem Biophys Res Commun. 2015;460:983-8 pubmed publisher

Yang C, Huang Y, Tsai M, Cheng C, Liu L, Yen Y, et al. Inhibition of melanogenesis by β-caryophyllene from lime mint essential oil in mouse B16 melanoma cells. Int J Cosmet Sci. 2015;37:550-4 pubmed publisher

Nagiec M, Skepner A, Negri J, Eichhorn M, Kuperwasser N, Comer E, et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLoS ONE. 2015;10:e0120295 pubmed publisher

Shazly G, Mohsin K. Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material. Acta Pharm. 2015;65:29-42 pubmed publisher

Cherian M, Lin W, Wu J, Chen T. CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor. Mol Pharmacol. 2015;87:878-89 pubmed publisher

Li X, Zhou J, Zou S, Yu J, Meng X, Wu J. Enhancement of radiosensitivity in human esophageal carcinoma cells by fenofibrate and its potential mechanism. Tumori. 2015;101:123-30 pubmed

Yang C, Kim J, Kim T, Lee P, Kim S, Lee H, et al. Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome. Nat Commun. 2015;6:6115 pubmed publisher

Lu Y, Cheng J, Chen L, Li C, Chen G, Gui L, et al. Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention. Biochem Biophys Res Commun. 2015;458:1-7 pubmed publisher

Hsu Y, Wang L, Yang W, Yang C, Yang C. Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats. J Diabetes Res. 2014;2014:540326 pubmed publisher

Zhang H, Shao Z, Alibin C, Acosta C, Anderson H. Liganded peroxisome proliferator-activated receptors (PPARs) preserve nuclear histone deacetylase 5 levels in endothelin-treated Sprague-Dawley rat cardiac myocytes. PLoS ONE. 2014;9:e115258 pubmed publisher

Takahashi H, Goto T, Yamazaki Y, Kamakari K, Hirata M, Suzuki H, et al. Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α. J Lipid Res. 2015;56:254-65 pubmed publisher

Creusot N, Brion F, Piccini B, Budzinski H, Porcher J, Aït Aïssa S. BFCOD activity in fish cell lines and zebrafish embryos and its modulation by chemical ligands of human aryl hydrocarbon and nuclear receptors. Environ Sci Pollut Res Int. 2015;22:16393-404 pubmed publisher

Lee W, Tan J, Tan C, Loo S. Modulating drug release from gastric-floating microcapsules through spray-coating layers. PLoS ONE. 2014;9:e114284 pubmed publisher

Frank R. Systemic therapies for diabetic retinopathy: the accord eye study. Ophthalmology. 2014;121:2295-6 pubmed publisher

Mason R, Jacob R. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502-9 pubmed publisher

Khera A, Qamar A, Reilly M, Dunbar R, Rader D. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol. 2015;115:178-82 pubmed publisher

Piwowarczyk K, Wybieralska E, Baran J, Borowczyk J, Rybak P, Kosińska M, et al. Fenofibrate enhances barrier function of endothelial continuum within the metastatic niche of prostate cancer cells. Expert Opin Ther Targets. 2015;19:163-76 pubmed publisher

Sur A, Kesaraju S, Prentice H, Ayyanathan K, Baronas Lowell D, Zhu D, et al. Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci U S A. 2014;111:16754-9 pubmed publisher

Patil H, Feng X, Ye X, Majumdar S, Repka M. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach. AAPS J. 2015;17:194-205 pubmed publisher

Wilk A, Wyczechowska D, Zapata A, DEAN M, Mullinax J, Marrero L, et al. Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death. Mol Cell Biol. 2015;35:182-98 pubmed publisher

Balakumar P, Varatharajan R, Nyo Y, Renushia R, Raaginey D, Oh A, et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res. 2014;90:36-47 pubmed publisher

Nakagawa Y, Satoh A, Yabe S, Furusawa M, Tokushige N, Tezuka H, et al. Hepatic CREB3L3 controls whole-body energy homeostasis and improves obesity and diabetes. Endocrinology. 2014;155:4706-19 pubmed publisher

Mahmoud A, Elshazly S. Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLoS ONE. 2014;9:e106993 pubmed publisher

Chew E, Davis M, Danis R, Lovato J, Perdue L, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014;121:2443-51 pubmed publisher

Lehman A, Montford J, Horita H, Ostriker A, Weiser Evans M, Nemenoff R, et al. Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells. Mol Pharmacol. 2014;86:570-9 pubmed publisher

Liu J, Ge Y, Zhu H, Yang X, Cai J, Zhang C, et al. Fenofibrate increases radiosensitivity in head and neck squamous cell carcinoma via inducing G2/M arrest and apoptosis. Asian Pac J Cancer Prev. 2014;15:6649-55 pubmed

Rommelaere S, Millet V, Vu Manh T, Gensollen T, Andreoletti P, Cherkaoui Malki M, et al. Sox17 regulates liver lipid metabolism and adaptation to fasting. PLoS ONE. 2014;9:e104925 pubmed publisher

Massin P, Peto T, Ansquer J, Aubonnet P, MacuFEN Study Investigators F. Effects of fenofibric acid on diabetic macular edema: the MacuFen study. Ophthalmic Epidemiol. 2014;21:307-17 pubmed publisher

Ferguson L, Most D, Blednov Y, Harris R. PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. Neuropharmacology. 2014;86:397-407 pubmed publisher

Berthelsen R, Sjögren E, Jacobsen J, Kristensen J, Holm R, Abrahamsson B, et al. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example. Int J Pharm. 2014;473:356-65 pubmed publisher

Williams H, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. J Pharm Sci. 2014;103:2441-55 pubmed publisher

McIntosh A, Huang H, Storey S, Landrock K, Landrock D, Petrescu A, et al. Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-? activation in cultured human female hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2014;307:G164-76 pubmed publisher

Rosas J, de Waard H, De Beer T, Vervaet C, Remon J, Hinrichs W, et al. NIR spectroscopy for the in-line monitoring of a multicomponent formulation during the entire freeze-drying process. J Pharm Biomed Anal. 2014;97:39-46 pubmed publisher

Downing N, Cheng T, Krumholz H, Shah N, Ross J. Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. JAMA Intern Med. 2014;174:1176-82 pubmed publisher

Tancevski I, Nairz M, Duwensee K, Auer K, Schroll A, Heim C, et al. Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2. EMBO Mol Med. 2014;6:810-20 pubmed publisher

Williams H, Van Speybroeck M, Augustijns P, Porter C. Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance. J Pharm Sci. 2014;103:1734-46 pubmed publisher

Shen W, Gao Y, Lu B, Zhang Q, Hu Y, Chen Y. Negatively regulating TLR4/NF-?B signaling via PPAR? in endotoxin-induced uveitis. Biochim Biophys Acta. 2014;1842:1109-20 pubmed publisher

Haas M, Onstead Haas L, Naem E, Wong N, Mooradian A. Induction of apolipoprotein A-I gene expression by black seed (Nigella sativa) extracts. Pharm Biol. 2014;52:1119-27 pubmed publisher

Ferreira A, Menezes Garcia Z, Mario E, Delpuerto H, Martins A, Botion L. Increased expression of oxidative enzymes in adipose tissue following PPARα-activation. Metabolism. 2014;63:456-60 pubmed publisher

Huang W, Chen L, Zhang B, Park M, Toborek M. PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. J Cereb Blood Flow Metab. 2014;34:646-53 pubmed publisher

Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia R, et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. Leukemia. 2014;28:1381-7 pubmed publisher

Koshy J, Koshy J, Thomas S, Kaur G, Mathew T. Should we start all patients with diabetic retinopathy on fenofibrates?. Middle East Afr J Ophthalmol. 2013;20:309-14 pubmed publisher

Lingam G, Wong T. Systemic medical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:301-8 pubmed publisher

Martin G, McIntosh A, Huang H, Gupta S, Atshaves B, Landrock K, et al. The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates. Biochemistry. 2013;52:9347-57 pubmed publisher

Noonan J, Jenkins A, Ma J, Keech A, Wang J, Lamoureux E. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62:3968-75 pubmed publisher

Robison N, Campigotto F, Chi S, Manley P, Turner C, Zimmerman M, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61:636-42 pubmed publisher

Sullivan M, Katon W, Lovato L, Miller M, Murray A, Horowitz K, et al. Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry. 2013;70:1041-7 pubmed publisher

Muñoz M, Liu W, Delaney J, Brown E, Mugavero M, Mathews W, et al. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr. 2013;64:254-60 pubmed publisher

Yang J, Luo W, Chen L, Dai R, Liu A. Metabolism of fenofibrate in beagle dogs: new metabolites identified and metabolic pathways revealed. Pharmazie. 2013;68:414-20 pubmed

Huang Y, Liu K, Chiou Y, Yang C, Chen T, Li T, et al. Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway. Chem Biol Interact. 2013;205:157-64 pubmed publisher

Hiyama Y, Marshall A, Kraft R, Arno A, Jeschke M. Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress. J Surg Res. 2013;185:733-9 pubmed publisher

Soyoral Y, Canbaz E, Erdur M, Emre H, Begenik H, Erkoc R. Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. J Pak Med Assoc. 2012;62:849-51 pubmed

Attridge R, Frei C, Ryan L, Koeller J, Linn W. Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm. 2013;70:1219-25 pubmed publisher

Walker A, Kaplon R, Lucking S, Russell Nowlan M, Seals D. Response to effect of fenofibrate on vascular endothelial function: statistical appraisal and its validity. Hypertension. 2013;61:e56 pubmed

Trottier J, Perreault M, Rudkowska I, Levy C, Dallaire Theroux A, Verreault M, et al. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate. Clin Pharmacol Ther. 2013;94:533-43 pubmed publisher

Petrescu A, McIntosh A, Storey S, Huang H, Martin G, Landrock D, et al. High glucose potentiates L-FABP mediated fibrate induction of PPAR? in mouse hepatocytes. Biochim Biophys Acta. 2013;1831:1412-25 pubmed publisher

Simo R, Roy S, Behar Cohen F, Keech A, Mitchell P, Wong T. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem. 2013;20:3258-66 pubmed

Kim E, Isoda F, Kurland I, Mobbs C. Glucose-induced metabolic memory in Schwann cells: prevention by PPAR agonists. Endocrinology. 2013;154:3054-66 pubmed publisher

Xu Y, Wang Y, Li X, Huang Q, Chen W, Liu R, et al. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats. Drug Dev Ind Pharm. 2014;40:972-9 pubmed publisher

Huang J, Das S, Jha P, Al Zoughbi W, Schauer S, Claudel T, et al. The PPAR? agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta. 2013;1831:1555-65 pubmed publisher

Wang W, Lin Q, Lin R, Zhang J, Ren F, Zhang J, et al. PPAR? agonist fenofibrate attenuates TNF-?-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res. 2013;319:1523-33 pubmed publisher

Kawada T. Effect of fenofibrate on vascular endothelial function: statistical appraisal and its validity. Hypertension. 2013;61:e55 pubmed publisher

Al Waili K, Al Zakwani I, Al Dughaishi T, Baneerje Y, Al Sabti H, Al Hashmi K, et al. Comparison of therapeutic lipid target achievements among high-risk patients in Oman. Angiology. 2014;65:430-5 pubmed publisher

Vazzana N, Ganci A, Cefalù A, Lattanzio S, Noto D, Santoro N, et al. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J Am Heart Assoc. 2013;2:e000063 pubmed publisher

Susecov A. [Fibric acid derivatives: focus on fenofibrate]. Kardiologiia. 2013;53:79-86 pubmed

Kostapanos M, Florentin M, Elisaf M. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43:522-31 pubmed publisher

Upreti V, Dhull P, Patnaik S, Kumar K. An unusual cause of delayed puberty: Berardinelli- Seip syndrome. J Pediatr Endocrinol Metab. 2012;25:1157-60 pubmed

Roedder S, Kimura N, Okamura H, Hsieh S, Gong Y, Sarwal M. Significance and suppression of redundant IL17 responses in acute allograft rejection by bioinformatics based drug repositioning of fenofibrate. PLoS ONE. 2013;8:e56657 pubmed publisher

Cziraky M, Willey V, McKenney J, Kamat S, Fisher M, Guyton J, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7:102-8 pubmed publisher

Zhao H, Zhu C, Qin C, Tao T, Li J, Cheng G, et al. Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP. Biochem Biophys Res Commun. 2013;432:320-5 pubmed publisher

He W, Lu Y, Qi J, Chen L, Hu F, Wu W. Nanoemulsion-templated shell-crosslinked nanocapsules as drug delivery systems. Int J Pharm. 2013;445:69-78 pubmed publisher

Gilbert K, Nian H, Yu C, Luther J, Brown N. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens. 2013;31:820-9 pubmed publisher

Miller T, Breyer S, van Colen G, Mier W, Haberkorn U, Geissler S, et al. Premature drug release of polymeric micelles and its effects on tumor targeting. Int J Pharm. 2013;445:117-24 pubmed publisher

Koh K. Does fenofibrate lower blood pressure?. Hypertension. 2013;61:e27 pubmed publisher

Kostapanos M, Athyros V, Mikhailidis D, Elisaf M. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J Clin Lipidol. 2013;7:88 pubmed publisher

Chan S, Sun R, Zeng X, Choong Z, Wang H, Watt M, et al. Activation of PPAR? ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes. 2013;62:2095-105 pubmed publisher

Glineur C, Gross B, Neve B, Rommens C, Chew G, Martin Nizard F, et al. Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor ?-dependent and independent mechanisms in human endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33:621-8 pubmed publisher

Babbar L, Mahadevan N, Balakumar P. Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:319-29 pubmed publisher

Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol. 2013;40:219-26 pubmed publisher

Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29:181-8 pubmed publisher

Tyagi S, Lemke E. Genetically encoded click chemistry for single-molecule FRET of proteins. Methods Cell Biol. 2013;113:169-87 pubmed publisher

Roth E, Rosenson R, Jones P, Davidson M, Kelly M, Setze C, et al. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012;6:534-44 pubmed publisher

Stillhart C, Cavegn M, Kuentz M. Study of drug supersaturation for rational early formulation screening of surfactant/co-solvent drug delivery systems. J Pharm Pharmacol. 2013;65:181-92 pubmed publisher

ABCOUWER S. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes. 2013;62:36-8 pubmed publisher

Li M, Ma J, Su T, Liu M, Phillips D. A time-resolved spectroscopy and density functional theory study of the solvent dependent photochemistry of fenofibric acid. Phys Chem Chem Phys. 2013;15:1557-68 pubmed publisher

Kim G, Poudel B, Marasini N, Lee D, Hiep T, Yang K, et al. Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems. Drug Dev Ind Pharm. 2013;39:1431-8 pubmed publisher

Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110:1296-301 pubmed publisher

Wong T, Simo R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy?. Am J Ophthalmol. 2012;154:6-12 pubmed publisher

Farnier M. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. Expert Rev Cardiovasc Ther. 2012;10:565-75 pubmed publisher

Elijah I, Børsheim E, Maybauer D, Finnerty C, Herndon D, Maybauer M. Role of the PPAR-? agonist fenofibrate in severe pediatric burn. Burns. 2012;38:481-6 pubmed publisher

Susekov A, Khokhlova N. [Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?]. Kardiologiia. 2011;51:68-74 pubmed

McKeage K, Keating G. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011;71:1917-46 pubmed publisher

Simo R, Hernandez C. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. Rev Recent Clin Trials. 2012;7:71-80 pubmed

Filippatos T, Elisaf M. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945-58 pubmed publisher

Keating G. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011;11:227-47 pubmed publisher

Hermans M. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011;8:180-9 pubmed publisher

Wright A, Dodson P. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond). 2011;25:843-9 pubmed publisher

Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actions of fenofibrate on the heart. Pharmacol Res. 2011;63:8-12 pubmed publisher

Kucera M, Oravec S, Ocadlik I. [The significance of fenofibrate in the therapy of atherogenic dyslipoproteinaemia]. Vnitr Lek. 2010;56:865-70 pubmed

Agouridis A, Filippatos T, Derdemezis C, Mikhailidis D, Elisaf M. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010;16:3401-16 pubmed

Samineni D, Fichtenbaum C. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol. 2010;6:995-1004 pubmed publisher

Foucher C, Brugère L, Ansquer J. Fenofibrate, homocysteine and renal function. Curr Vasc Pharmacol. 2010;8:589-603 pubmed

Wouters K, van Bilsen M, van Gorp P, Bieghs V, Lutjohann D, Kerksiek A, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010;584:1001-5 pubmed publisher

Huang X, Zhao S, Bai L, Hu M, Zhao W, Zhang Q. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol. 2009;158:706-12 pubmed publisher

Chen W, Zhou X, Liu H, Xu C, Wang L, Li S. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice. Br J Pharmacol. 2009;157:724-35 pubmed publisher

Chaput E, Maubrou Sanchez D, Bellamy F, Edgar A. Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol. Lipids. 1999;34:497-502 pubmed